Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems

Microsomal enzymes catalyze Phase I oxidation reactions, utilizing molecular oxygen and NADPH as cofactors. These enzymes facilitate the incorporation of one oxygen atom into drug molecules, enhancing their hydrophilicity. This oxidative process is fundamental to transforming lipophilic drugs into polar metabolites that the body can readily excrete.

Aromatic carbons, such as those in phenobarbital, undergo oxidation to form intermediate epoxides that rearrange into hydroxylated metabolites like hydroxyphenobarbital. This aromatic hydroxylation reduces the pharmacological activity of the parent drug. Similar processes occur in other aromatic drugs like phenytoin, producing p-hydroxy phenytoin as a metabolite.

Aliphatic carbons undergo terminal oxidation to yield hydroxy metabolites, as seen in valproic acid metabolism. Benzylic and allylic carbons are oxidized to carbinols, then further oxidized to carbonyl compounds and acids, exemplified by tolbutamide and hexobarbital. These sequential oxidations progressively increase metabolite polarity for elimination.

Oxidative reactions can generate reactive metabolites that cause toxicological activation of drugs. Acetaminophen exemplifies this risk: its conversion to reactive metabolites can trigger hepatic necrosis. Understanding these potentially harmful transformations underscores the importance of monitoring drug metabolism and predicting adverse effects during drug development.

Alpha carbons adjacent to carbonyl or imine groups are readily hydroxylated during Phase I metabolism. Diazepam exemplifies this process, undergoing hydroxylation at the alpha position. This hydroxylation introduces polar functional groups that facilitate subsequent conjugation and elimination of the drug from the body.

Alicyclic carbon atoms, such as those in minoxidil, are typically hydroxylated at the C-3 or C-4 positions during Phase I metabolism. These site-specific hydroxylations introduce polar functional groups into the cyclic structure. The resulting hydroxylated metabolites are more hydrophilic and readily eliminated compared to the parent compound.

Phase I oxidation introduces or exposes polar functional groups on drugs, making them substrates for phase II conjugation reactions. These oxidized metabolites are more hydrophilic and contain reactive sites for conjugation with glutathione, sulfate, or glucuronic acid. This two-stage process ensures efficient transformation of lipophilic xenobiotics into water-soluble compounds for renal excretion.